Calamos Advisors
IBB icon

Calamos Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Calamos Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-398,000
Closed -$57.5M – 1236
2025
Q4 		$57.5M Buy
398,000
+16,800
+4% +$2.73M 0.22% 110
2025
Q3 		$48.2M Buy
+381,200
New +$52M 0.18% 127

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Calamos Advisors's IBB Position: Q1 2026 in Review

Calamos Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 168,310 shares — an estimated $28.4M sold.

Calamos Advisors first reported a position in IBB in Q1 2017 and held it in 20 quarters. The position peaked at $28.4M in Q4 2025. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Calamos Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
  • Calamos Advisors sold 168,310 iShares Biotechnology ETF shares in Q1 2026, an estimated $28.4M.
  • Calamos Advisors first reported a position in iShares Biotechnology ETF in Q1 2017 and held it in 20 quarters.
  • Calamos Advisors's iShares Biotechnology ETF position peaked at $28.4M in Q4 2025.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.